Risk of Gastrointestinal Bleed and Endoscopic Procedures on Antiplatelet and Antithrombotic Agents

ABSTRACT

The use of antiplatelet and antithrombotic agents has increased hand in hand with the number and complexity of endoscopic procedures. Hence, the endoscopists are often faced with considering endoscopy in patients on these agents. In this setting, to make informed decision, four key aspects are need to be considered. The type of antithrombotic or antiplatelet agent used and its characteristics, risk of thromboembolic events (which can lead to ischemic stroke or acute coronary syndrome, both of which carry high morbidity) due to withholding the drug, risk of bleeding (increases with invasiveness of procedure), and timing of procedure (elective or urgent) are the key factors to consider. We aim to discuss the risk of gastrointestinal bleed and endoscopic procedures on antiplatelet and antithrombotic agents focusing on Indian context based on recent Asia?pacific guidelines along with other existing guidelines.

KEYWORDS

Antiplatelets - antithrombotic agents - endoscopy - gastrointestinal bleeding

• REFERENCES

• 1 Goodman LS, Brunton LL, Chabner B, Knollmann BC. Goodman & Gilman’s Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 2011
• 2 Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J. Harrison’s Principles of Internal Medicine. 19th ed. New York: McGraw Hill Education; 2015
• 3 Chan FK, Goh KL, Reddy N, Fujimoto K, Ho KY, Hokimoto S. et al. Management of patients on antithrombotic agents undergoing emergency and elective endoscopy: Joint Asian Pacific Association of Gastroenterology (APAGE) and Asian pacific Society for Digestive Endoscopy (APSDE) practice guidelines. Gut 2018; 67: 405-17
• 4 Hawn MT, Graham LA, Richman JS, Itani KM, Henderson WG, Maddox TM. et al. Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents. JAMA 2013; 310: 1462-72
• 5 Fleisher LA, Fleischmann KE, Auerbach AD, Barnason SA, Beckman JA, Bozkurt B. et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: A report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol 2014; 64: e77-137
• 6 Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH. et al. Perioperative management of antithrombotic therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141: e326S-50S
• 7 Douketis JD, Healey JS, Brueckmann M, Eikelboom JW, Ezekowitz MD, Fraessdorf M. et al. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. Thromb Haemost 2015; 113: 625-32
• 8 Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS. et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med 2015; 373: 823-33
• 9 Veitch AM, Vanbiervliet G, Gershlick AH, Boustiere C, Baglin TP, Smith LA. et al. Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British society of gastroenterology (BSG) and European society of gastrointestinal endoscopy (ESGE) guidelines. Gut 2016; 65: 374-89
• 10 ASGE Standards of Practice Committee. Acosta RD, Abraham NS, Chandrasekhara V, Chathadi KV, Early DS. et al. The management of antithrombotic agents for patients undergoing GI endoscopy. Gastrointest Endosc 2016; 83: 3-16
• 11 Foley P, Foley S, Kinnaird T, Anderson RA. Clinical review: Gastrointestinal bleeding after percutaneous coronary intervention: A deadly combination. QJM 2008; 101: 425-33
• 12 Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK. et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent anticoagulation restenosis study investigators. N Engl J Med 1998; 339: 1665-71
• 13 Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK. et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001; 358: 527-33
• 14 Moscucci M, Fox KA, Cannon CP, Klein W, López-Sendón J, Montalescot G. et al. Predictors of major bleeding in acute coronary syndromes: The Global Registry of acute Coronary Events (GRACE). Eur Heart J 2003; 24: 1815-23
• 15 Al-Mallah M, Bazari RN, Jankowski M, Hudson MP. Predictors and outcomes associated with gastrointestinal bleeding in patients with acute coronary syndromes. J Thromb Thrombolysis 2007; 23: 51-55
• 16 Abbas AE, Brodie B, Dixon S, Marsalese D, Brewington S, O’Neill WW. et al. Incidence and prognostic impact of gastrointestinal bleeding after percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol 2005; 96: 173-176
• 17 Atar S, Cannon CP, Murphy SA, Rosanio S, Uretsky BF, Birnbaum Y. Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: Analysis of the orbofiban in patients with unstable coronary syndromes-thrombolysis in myocardial infarction 16 (OPUS-TIMI 16) trial. Am Heart J 2006; 151 (976) e1-6
• 18 Hallas J, Dall M, Andries A, Andersen BS, Aalykke C, Hansen JM. et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: Population based case-control study. BMJ 2006; 333: 726
• 19 Hui AJ, Wong RM, Ching JY, Hung LC, Chung SC, Sung JJ. et al. Risk of colonoscopic polypectomy bleeding with anticoagulants and antiplatelet agents: Analysis of 1657 cases. Gastrointest Endosc 2004; 59: 44-8
• 20 Nelson DB, Freeman ML. Major hemorrhage from endoscopic sphincterotomy: Risk factor analysis. J Clin Gastroenterol 1994; 19: 283-87
• 21 Yousfi M, Gostout CJ, Baron TH, Hernandez JL, Keate R, Fleischer DE. et al. Postpolypectomy lower gastrointestinal bleeding: Potential role of aspirin. Am J Gastroenterol 2004; 99: 1785-9
• 22 Cho SJ, Choi IJ, Kim CG, Lee JY, Nam BH, Kwak MH. et al. Aspirin use and bleeding risk after endoscopic submucosal dissection in patients with gastric neoplasms. Endoscopy 2012; 44: 114-21
• 23 Burgess NG, Metz AJ, Williams SJ, Singh R, Tam W, Hourigan LF. et al. Risk factors for intraprocedural and clinically significant delayed bleeding after wide-field endoscopic mucosal resection of large colonic lesions. Clin Gastroenterol Hepatol 2014; 12: 651-61
• 24 Metz AJ, Bourke MJ, Moss A, Williams SJ, Swan MP, Byth K. et al. Factors that predict bleeding following endoscopic mucosal resection of large colonic lesions. Endoscopy 2011; 43: 506-11
• 25 Sung JJ, Lau JY, Ching JY, Wu JC, Lee YT, Chiu PW. et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: A randomized trial. Ann Intern Med 2010; 152: 1-9
• 26 Zakko L, Rustagi T, Douglas M, Laine L. No benefit from platelet transfusion for gastrointestinal bleeding in patients taking antiplatelet agents. Clin Gastroenterol Hepatol 2017; 15: 46-52
• 27 Kukreja N, Onuma Y, Garcia-Garcia HM, Daemen J, van Domburg R, Serruys PW. et al. The risk of stent thrombosis in patients with acute coronary syndromes treated with bare-metal and drug-eluting stents. JACC Cardiovasc Interv 2009; 2: 534-41
• 28 Eisenberg MJ, Richard PR, Libersan D, Filion KB. Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents. Circulation 2009; 119: 1634-42
• 29 Yamada S, Onda M, Kato S, Matsuda N, Matsuhisa T, Yamada N. et al. Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations. J Gastroenterol 2001; 36: 669-72
• 30 Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-57
• 31 Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-15
• 32 Zeymer U, Hochadel M, Lauer B, Kaul N, Wöhrle J, Andresen D. et al. Use, efficacy and safety of prasugrel in patients with ST segment elevation myocardial infarction scheduled for primary percutaneous coronary intervention in clinical practice. Results of the prospective ATACS-registry. Int J Cardiol 2015; 184: 122-7
• 33 Choudari CP, Rajgopal C, Palmer KR. Acute gastrointestinal haemorrhage in anticoagulated patients: Diagnoses and response to endoscopic treatment. Gut 1994; 35: 464-6
• 34 Wolf AT, Wasan SK, Saltzman JR. Impact of anticoagulation on rebleeding following endoscopic therapy for nonvariceal upper gastrointestinal hemorrhage. Am J Gastroenterol 2007; 102: 290-6
• 35 Karaca MA, Erbil B, Ozmen MM. Use and effectiveness of prothrombin complex concentrates vs. fresh frozen plasma in gastrointestinal hemorrhage due to warfarin usage in the ED. Am J Emerg Med 2014; 32: 660-4
• 36 Patel RJ, Witt DM, Saseen JJ, Tillman DJ, Wilkinson DS. Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation. Pharmacotherapy 2000; 20: 1159-66
• 37 Crowther MA, Julian J, McCarty D, Douketis J, Kovacs M, Biagoni L. et al. Treatment of warfarin-associated coagulopathy with oral vitamin K: A randomised controlled trial. Lancet 2000; 356: 1551-3
• 38 Eikelboom JW, Hankey GJ. Low molecular weight heparins and heparinoids. Med J Aust 2002; 177: 379-83
• 39 Lee JK, Kang HW, Kim SG, Kim JS, Jung HC. Risks related with withholding and resuming anticoagulation in patients with non-variceal upper gastrointestinal bleeding while on warfarin therapy. Int J Clin Pract 2012; 66: 64-8
• 40 Wang X, Mondal S, Wang J, Tirucherai G, Zhang D, Boyd RA. et al. Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Am J Cardiovasc Drugs 2014; 14: 147-54
• 41 Pollack Jr CV, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA. et al. Idarucizumab for dabigatran reversal – Full cohort analysis. N Engl J Med 2017; 377: 431-41
• 42 Khadzhynov D, Wagner F, Formella S, Wiegert E, Moschetti V, Slowinski T. et al. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Thromb Haemost 2013; 109: 596-605
• 43 Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-9
• 44 Halvorsen S, Storey RF, Rocca B, Sibbing D, Ten Berg J, Grove EL. et al. Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: Expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J 2017; 38: 1455-62